

MSD Pipeline

1Q2026 Reflecting Pipeline to **20-Feb-2026**



Lead-in language

The chart below reflects the company's research pipeline as of **20-Feb-2026**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer, immunology and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.

- 1. Being developed in a collaboration.
- ▶ Moved forward since last pipeline update.

MSD pipeline as of 20-Feb-2026

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Biliary Bladder Cervical Endometrial Esophageal Gastric HCC HNSCC Melanoma NSCLC Ovarian Pancreatic Prostate patritumab deruxtecan MK-1022¹	▶ Solid Tumors calderasib MK-1084¹	Alzheimer's Disease MK-1167	Alzheimer's Disease MK-2214	Cancer Biliary Bladder Breast Cervical Endometrial HCC HNSCC Melanoma NSCLC Ovarian Pancreatic ifinatamab deruxtecan MK-2400¹	Cancer Biliary Bladder Esophageal Neoplasm Malignant Pancreatic sacituzumab tirumotecan MK-2870¹
Cancer Bladder MK-3120	Cancer Prostate KEYTRUDA® MK-3475	Cancer Heme (US) KEYTRUDA QLEX™ MK-3475A	PH-COPD MK-5475	Cancer Breast Endometrial Ovarian opevesostat MK-5684	COPD ensifentrine (+) glycopyrrolate MK-5884A

- 1. Being developed in a collaboration.
- ▶ Moved forward since last pipeline update.

MSD pipeline as of 20-Feb-2026

Phase 2	Phase 2	Phase 2	Phase 2	Phase 2	Phase 2
Cancer Bladder Cervical Endometrial Gastric NSCLC RCC SCLC raludotatug deruxtecan MK-5909¹	MASH efinopegdutide MK-6024	Cancer SCLC gocatamig MK-6070¹	Cancer Breast WELIREG™ MK-6482	Immunology Axial Spondyloarthritis Hidradenitis Suppurativa Rheumatoid Arthritis Systemic Sclerosis tulisokibart MK-7240	Atherosclerosis MK-7262
Pulmonary Hypertension due to Left Heart Disease WINREVAIR™ MK-7962	HIV-1 Infection islatravir (+) ulonivirine MK-8591B	Eye Disorders MK-8748	Cancer Bladder RCC intismeran autogene V940¹		

MSD pipeline as of 20-Feb-2026

1. Being developed in a collaboration.
2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials.
3. Available in the U.S. under Emergency Use Authorization.
4. Program is in a Phase 2/3 study.

▶ Moved forward since last pipeline update.

Phase 3	Phase 3	Phase 3	Phase 3	Phase 3	Phase 3
Hypercholesterolemia enlicitide decanoate MK-0616	Cancer Breast patritumab deruxtecan MK-1022 ¹	Cancer Heme nemtabrutinib MK-1026	Cancer CRC NSCLC calderasib MK-1084 ¹	Cancer RCC quavonlimab (+) pembrolizumab MK-1308A	Influenza MK-1406
Cancer Heme zilovertamab vedotin MK-2140	Cancer Esophageal Prostate SCLC ifinatumab deruxtecan MK-2400 ¹	Cancer Breast Cervical Endometrial Gastric NSCLC Ovarian sacituzumab tirumotecan MK-2870 ¹	Diabetic Macular Edema MK-3000 ⁴	Cancer SCLC KEYTRUDA [®] MK-3475	Cancer Myeloproliferative Disorders bomedemstat MK-3543
COVID-19 LAGEVRIO [®] MK-4482 ^{1, 3} (US)	Cancer Prostate opevesostat MK-5684	Ovarian raludotatug deruxtecan MK-5909 ¹	Immunology Crohn's Disease Ulcerative Colitis tulisokibart MK-7240	Cancer NSCLC SCLC LYNPARZA [®] MK-7339 ¹	HIV-1 PrEP MK-8527
HIV-1 Infection doravirine (+) islatravir MK-8591A (EU)	HIV-1 Infection islatravir (+) lenacapavir MK-8591D ^{1,2}	Dengue Fever Virus Vaccine V181	Cancer Melanoma NSCLC intismeran autogene V940 ¹		

MSD pipeline as of 20-Feb-2026

1. Being developed in a collaboration.
2. Under review for combination use with KEYTRUDA® or KEYTRUDA QLEX™.

▶ Moved forward since last pipeline update.

New Molecular Entities Under Review	New Molecular Entities Under Review
Respiratory Syncytial Virus clesrovimab MK-1654 ENFLONIA™ (EU, JPN)	HIV-1 Infection doravirine (+) islatravir MK-8591A (US, JPN)

Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review	Certain Supplemental Filings Under Review
▶ Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) KEYTRUDA® MK-3475 (EU, JPN)	▶ First Line Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (KND19) KEYTRUDA® MK-3475 (US)	▶ First Line Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer (KND19) KEYTRUDA QLEX™ MK-3475A (US)
▶ Platinum-Resistant Recurrent Ovarian Cancer (KNB96) KEYTRUDA® MK-3475 (EU, JPN)	▶ Clear Cell Renal Cell Carcinoma Following Nephrectomy (LITESPARK-022) WELIREG® MK-6482^{1,2} (US)	▶ Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-011) WELIREG® MK-6482¹ (US)
▶ Pulmonary Arterial Hypertension (HYPERION) WINREVAIR™ MK-7962 (US)		

MSD pipeline as of 20-Feb-2026

1. Approvals obtained within the last 3 months.
2. MK-3475A to be marketed under the trade name KEYTRUDA SC in the EU.

▶ Moved forward since last pipeline update.

New Molecular Entities Approvals ¹	New Molecular Entities Approvals ¹
▶ Previously Approved Tumors KEYTRUDA QLEX™ MK-3475A² (EU)	▶ Pulmonary Arterial Hypertension (STELLAR) WINREVAIR™ MK-7962 (CHN)

Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹	Certain Supplemental Approvals ¹
▶ Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) KEYTRUDA® MK-3475 (US)	▶ Cisplatin Ineligible Muscle Invasive Bladder Cancer (KN905) KEYTRUDA QLEX™ MK-3475A (US)	▶ Platinum-Resistant Recurrent Ovarian Cancer (KNB96) KEYTRUDA® MK-3475 (US)
▶ Platinum-Resistant Recurrent Ovarian Cancer (KNB96) KEYTRUDA QLEX™ MK-3475A (US)	▶ Primary Advanced or Recurrent Endometrial Carcinoma (KN868) KEYTRUDA® MK-3475 (CHN)	▶ Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (KN689) KEYTRUDA® MK-3475 (JPN)
▶ Adults with Pulmonary Arterial Hypertension (WHO Functional Class (FC) II to III, and IV) (ZENITH) WINREVAIR™ MK-7962 (EU)		

Forward-looking statement

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No duty to update

The information contained in the presentation set forth below was current as of **20-Feb-2026**. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after **20-Feb-2026**.

The chart reflects the MSD research pipeline as of **20-Feb-2026**.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.